Sorry, I should have been more specific -- I wasn't talking about the whole year I was talking about peak volumes in 2009 just before or approaching the FDA Advisory Committee meeting on HEB's CFS NDA vs the peak volumes now approaching the Biotech Showcase and 'new data'.
The contrast being a pending NDA approval for a new class of drug and disease vs some new data on either ampligen or alferon (my guess is flumist/ampligen). The contrast in events is remarkable, given the volumes.
Market Data 
Markets 
AI
